There are currently 104 active clinical trials seeking participants for Asthma research studies. The states with the highest number of trials for Asthma participants are California, Texas, Florida and Ontario.
A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants 12 Years of Age and Older With Asthma
NCT06261957
Recruiting
The goal of this study is to assess and compare the safety and tolerability of salbutamol administered via metered dose inhaler (MDI) containing propellant 1,1-difluoroethane (HFA-152a) or 1,1,1,2-tetrafluoroethane (HFA-134a) in participants aged 12 years and above with asthma.
Gender:
All
Ages:
12 years and above
Trial Updated:
06/10/2024
Locations: GSK Investigational Site, Aventura, Florida +105 locations
Conditions: Asthma
Register for Updates
Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease
NCT04624490
Recruiting
The purpose of this study is to develop and evaluate the usefulness of hyperpolarized (HP) 129Xe gas MRI for regional assessment of pulmonary function.
Gender:
All
Ages:
3 years and above
Trial Updated:
06/07/2024
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Asthma, COPD, Interstitial Lung Disease, Cystic Fibrosis, Pulmonary Hypertension, Pulmonary Infection, Other Lung Disease
Register for Updates
Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)
NCT04609904
Recruiting
This is a variable length study to evaluate the efficacy and safety of budesonide/glycopyrronium/formoterol inhaler in adults and adolescents with severe asthma inadequately controlled with standard of care.
Gender:
All
Ages:
Between 12 years and 80 years
Trial Updated:
06/06/2024
Locations: Research Site, Muscle Shoals, Alabama +457 locations
Conditions: Asthma
Register for Updates
Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA
NCT06020014
Recruiting
This is a Phase 2a, multicentre, randomised, placebo-controlled, double-blind, parallel-group study to evaluate the efficacy, safety and PK of AZD4604 administered BID using a dry-powder inhaler at one dose level over a 12-week Treatment period in adult participants with uncontrolled moderate-to-severe asthma.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
06/05/2024
Locations: Research Site, Birmingham, Alabama +142 locations
Conditions: Asthma
Register for Updates
PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction
NCT05555290
Recruiting
A study evaluating efficacy and safety of repeated doses of PT027 compared to PT007 in patients with asthma and acute airway obstruction induced by repeated mannitol challenges
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
06/05/2024
Locations: Research Site, Columbia, Maryland +1 locations
Conditions: Asthma
Register for Updates
Comparison of Microglial Activation in Severe Asthma and Healthy Controls
NCT06299592
Recruiting
The goal of this clinical trial is to learn about how asthma influences brain function. The main questions it aims to answer are: How airway inflammation in asthma affects the brain; and, Whether airway inflammation in asthma is related to symptoms of depression and anxiety Over the course of 3 visits, participants will: Complete questionnaires Complete computer tasks Undergo allergy skin test and breathing tests Give two blood samples Give a sputum sample Complete brain imaging scans Resear... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/03/2024
Locations: Center for Healthy Minds, Madison, Wisconsin
Conditions: Asthma
Register for Updates
Role of Genetic Factors in the Development of Lung Disease
NCT00001532
Recruiting
This study is designed to evaluate the genetics involved in the development of lung disease by surveying genes involved in the process of breathing and examining the genes in lung cells of patients with lung disease. The study will focus on defining the distribution of abnormal genes responsible for processes directly involved in different diseases affecting the lungs of patients and healthy volunteers. Optional CT Sub-study The standard CT scan will be compared to the low dose radiation CT s... Read More
Gender:
All
Ages:
Between 2 years and 90 years
Trial Updated:
05/31/2024
Locations: Suburban Hospital, Bethesda, Maryland +1 locations
Conditions: Cystic Fibrosis, Pulmonary Fibrosis, Tuberous Sclerosis, Asthma, Pulmonary Sarcoidosis
Register for Updates
Primary Care Implementation and Evaluation of Coach McLungs
NCT05059210
Recruiting
The goal of this study is to evaluate the implementation of the Coach McLungsSM shared decision making (SDM) intervention into primary care across a large healthcare system. Coach McLungsSM is a virtual evidence-based asthma intervention with built-in asthma education and clinical decision support. All asthma patients aged 5-17 who attend these practices will be assessed for uncontrolled asthma. Asthma exacerbations attributed to emergency department visits, hospitalizations, and oral steroid us... Read More
Gender:
All
Ages:
Between 5 years and 17 years
Trial Updated:
05/31/2024
Locations: Atrium Health, Charlotte, North Carolina
Conditions: Asthma
Register for Updates
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
NCT06191315
Recruiting
This is a parallel, Phase 3, 2-arm study to evaluate the efficacy and long-term safety of dupilumab treatment in children 2 to <6 years of age with uncontrolled asthma and/or recurrent severe asthmatic wheeze. The study will be conducted in 2 parts. Part A will be a 52-week, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of dupilumab in children aged 2 to <6 years old with uncontrolled asthma and/or recurrent severe asthmatic wheeze. At the end of Part A, al... Read More
Gender:
All
Ages:
Between 2 years and 5 years
Trial Updated:
05/30/2024
Locations: Newport Childrens Medical Group Site Number : 8400023, Newport Beach, California +15 locations
Conditions: Wheezing, Asthma
Register for Updates
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
NCT06033833
Recruiting
This is a study of amlitelimab for the treatment of participants with moderate-to-severe asthma. The study will have a double-blind treatment period until Week 24 for each participant and an open-label treatment period where each participant will receive open-label amlitelimab from Week 24 onwards. The purpose of this study is to evaluate long-term safety, tolerability, and efficacy of amlitelimab for the treatment of adult participants with moderate-to-severe asthma who have previously been enr... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/29/2024
Locations: Bensch Clinical Research LLC Site Number : 8400004, Stockton, California +36 locations
Conditions: Asthma
Register for Updates
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
NCT05097287
Recruiting
This is an interventional, randomized, parallel group, treatment, Phase 3b/4, double blind, 2-arm study to assess the effect of dupilumab compared to standard of care therapy on preventing or slowing the rate of lung function decline in adult patients with uncontrolled moderate to severe asthma. The estimated duration is 4±1 weeks of screening and run-in period, followed by a 3-year double blinded treatment period. There will be a post-treatment follow-up (FU) period up to 12 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/27/2024
Locations: Cullman Research Center, LLC Site Number : 8400001, Cullman, Alabama +214 locations
Conditions: Asthma
Register for Updates
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
NCT05757102
Recruiting
The primary purpose of this study is to evaluate the effects of Fluticasone Furoate (FF)/ Umeclidinium (UMEC)/ Vilanterol (VI) on lung function compared with FF/VI after 24 weeks of treatment.
Gender:
All
Ages:
Between 12 years and 17 years
Trial Updated:
05/24/2024
Locations: GSK Investigational Site, Birmingham, Alabama +80 locations
Conditions: Asthma
Register for Updates